TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE, ZL-1310, TOPOTECAN HYDROCHLORIDE clinical trials

A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody Drug Conjugate (ADC), Compared to Investigator’s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer

This study is testing a new drug, ZL-1310, for people with small cell lung cancer that has come back. It compares ZL-1310 to standard treatments to see if it works better and how it affects patients' lives.